BPC-157 + TB-500

What is BPC-157 + TB-500?

This is the pre-blended format, a single lyophilised vial co-formulated with BPC-157 5mg and TB-500 5mg, 10mg of total peptide under batch UKPL-855. The two compounds are chemically unrelated. BPC-157 is a 15-residue pentadecapeptide, GEPPPGKPADDAGLV, C₆₂H₉₈N₁₆O₂₂, 1419.53 g/mol, CAS 137525-51-0. TB-500 is the 43-residue N-terminally acetylated thymosin beta 4 sequence, C₂₁₂H₃₅₀N₅₆O₇₈S, 4963.4 g/mol, CAS 77591-33-4. Their individual mechanisms and literatures are documented on the separate BPC-157 and TB-500 product pages and are not restated here. What this page documents is the blend as a format: what co-formulation into one vial gives a researcher procedurally, what it removes in terms of independent control, the fact that equal mass is not equimolar, and the honest position that no controlled study has evaluated this specific combination. Supplied as lyophilised powder for in-vitro research use only, not a licensed medicine.

Pre-Blended Vial vs Two Separate Vials

The blended vial wins on procedure and loses on control. One vial means one reconstitution, one fill volume and one solution, removing a transfer step along with the sterility risk and volumetric error it carries, and giving both components a single reconstitution date and a single in-use window to track. Two separate vials win wherever the ratio has to be varied, wherever an observation needs attributing to one mechanism rather than the pair, or wherever one component is required without the other. There is also an arithmetic asymmetry inside the blend that separate vials make explicit and co-formulation hides: 5mg of a 1419.53 g/mol peptide is roughly 3.5 µmol, while 5mg of a 4963.4 g/mol peptide is roughly 1.0 µmol, so an equal-mass blend is close to a 3.5 to 1 molar ratio in favour of BPC-157. Analytically, a co-formulated vial also demands more of its certificate of analysis, which must resolve and assay two species of very different mass separately rather than reporting one aggregate figure.

BPC-157 + TB-500 Research Applications

The blend is used in preclinical soft-tissue and cell-migration research designs that would otherwise run the two compounds in parallel preparations, where the practical value is a single reconstitution and a single in-use window rather than any property arising from co-formulation. The underlying literatures remain separate and each is preclinical for musculoskeletal endpoints. BPC-157 work centres on local angiogenic signalling, with Hsieh and colleagues (J Mol Med, 2017) reporting VEGFR2 upregulation and internalisation in human endothelial cells, and Chang and colleagues (J Appl Physiol, 2011) reporting increased focal adhesion kinase and paxillin phosphorylation in cultured rat tendon fibroblasts. Thymosin beta 4 work centres on G-actin sequestration and integrin-linked kinase signalling, with Bock-Marquette and colleagues (Nature, 2004) reporting cell migration and survival effects in mouse cardiac injury models. No controlled study has tested the two in combination against either alone, so combination-specific claims cannot be supported. A 2025 scoping review by McGuire and colleagues (Curr Rev Musculoskelet Med) found no adequately powered randomised controlled trials for BPC-157 in musculoskeletal healing.

Reconstitution Guide

Treat the vial as a single 10mg preparation, with one fill volume set by the concentration your protocol specifies. Allow the vial and the bacteriostatic water to reach room temperature, swab both rubber stoppers with alcohol, then inject the diluent slowly down the inner glass wall rather than onto the lyophilised cake, and swirl gently until fully dissolved. Never shake or vortex. The 43-residue thymosin beta 4 chain is shear sensitive and agitation reduces recovery of intact peptide. The solution should be clear and colourless. Two points are specific to the blended format. First, the components cannot be separated after reconstitution, so protocols needing an independently chosen ratio require separate vials. Second, when expressing the preparation in molar terms, remember that the two components are present at roughly 3.5 µmol and 1.0 µmol respectively, not in equal molar amounts. Label the vial with the fill volume, resulting concentration and reconstitution date.

See our full peptide reconstitution guide and reconstitution calculator for step-by-step protocol.

Storage Instructions

Lyophilised vials should be stored at -20°C, protected from light and moisture, and remain stable for up to 24 months. Once reconstituted, hold the solution at 2-8°C, and prepare single-use aliquots at -20°C for anything beyond short-term use. Because both components share one reconstitution date in a co-formulated vial, the shorter of the two in-use windows governs the whole preparation rather than each component being managed independently. Avoid repeated freeze-thaw cycles, which reduce recovery of the 43-residue thymosin beta 4 chain in particular, label every aliquot with the reconstitution date, and handle throughout under sterile laboratory conditions.

Frequently Asked Questions

Research References

• Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation (Hsieh et al., J Mol Med, 2017)
• Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair (Bock-Marquette et al., Nature, 2004)
• Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing (McGuire et al., Curr Rev Musculoskelet Med, 2025)

Related Research Compounds

• → BPC-157 5mg (main product page)
• → TB-500 5mg (main product page)
• → Bacteriostatic Water 10ml